

OCT. 22. 2003 3:42PM

BSKB COM

NO. 8559 P. 1

650 Town Center Drive, Suite 620  
Costa Mesa, CA 92626-1925  
Phone: (714) 708-8555  
Fax: (714) 708-8565

**Birch, Stewart,  
Kolasch & Birch, LLP**

RECEIVED  
CENTRAL FAX CENTER

OCT 22 2003

**Fax**

OFFICIAL

**To:** Examiner Alana M. Harris **From:** Leonard R. Svensson  
**Fax:** 703-308-4315 **Pages:** 6 (including cover sheet)  
**Phone:** 703-306-5880 **Date:** October 22, 2003  
**Your Ref.:** 10/090,663 **Our Ref.:** 4518-0101P  
**Re:** Reply to Restriction Requirement **CC:**

☐ **Urgent** ☐ **For Review** ☐ **Please Comment** ☐ **Please Reply** ☐ **Please Recycle**

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited. If your receipt of this transmission is in error, please notify this firm immediately by collect call to (714) 708-8555, and send the original transmission to us by return mail at the address above.

● **Comments:**

Please find attached a transmittal and a Reply to Restriction Requirement.

PATENT  
4518-0101P

## IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Helmut Eckert Conf.: 8183  
Appl. No.: 10/090,663 Group: 1642  
Filed: March 5, 2002 Examiner: ALANA M HARRIS  
For: MONOCLONAL ANTIBODIES AND THEIR USE

LARGE ENTITY TRANSMITTAL FORM

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

October 22, 2003

Sir:

Transmitted herewith is a Reply to Restriction/Election Requirement in the above-identified application.

- ☐ The enclosed document is being transmitted via the Certificate of Mailing provisions of 37 C.F.R. § 1.8.
- ☒ The enclosed document is being transmitted via facsimile.
- ☒ Petition for one (1) month(s) extension of time pursuant to 37 C.F.R. §§ 1.17 and 1.136(a). \$110.00 for the extension of time.
- ☐ No fee is required.
- ☐ A check in the amount of \$0.00 is enclosed.
- ☒ Please charge Deposit Account No. 02-2448 in the amount of \$110.00. A triplicate copy of this sheet is attached.

RECEIVED  
CENTRAL FAX CENTER

OCT 22 2003

OFFICIAL

Appl. No. 10/090,663


If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. §§1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH &amp; BIRCH, LLP

By   
Leonard R. Svensson, #30,330

P.O. Box 747  
Falls Church, VA 22040-0747  
(714) 708-8555

Certificate of Transmission  
I hereby Certify that this correspondence is being  
facsimile transmitted to the Patent and  
Trademark Office.  
On October 22, 2003  
  
SANDRA B. PAULO  
Typed or printed name of person signing certificate

LRS/SWG/sbp  
4518-0101P

Attachment(s)

RECEIVED  
CENTRAL FAX CENTER

OCT 22 2003

OFFICIAL

PATENT  
4518-0101P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant:	Helmut Eckert	Conf.:	8183
Appl. No.:	10/090,663	Group:	1642
Filed:	March 5, 2002	Examiner:	Alana M HARRIS
For:	MONOCLONAL ANTIBODIES AND THEIR USE		

REPLY TO RESTRICTION REQUIREMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

October 22, 2003

Sir:

In response to the Restriction Requirement issued September 15, 2003, the period for response having been extended by one (1) month to November 15, 2003, the following remarks are respectfully submitted in connection with the above-identified application.

REMARKS

Claims 13-28 are pending in the present application.

The Examiner has required restriction to one of the following inventions:

Group I, claims 13-19, 23 and 28, drawn to a monoclonal murine internal image anti-idiotypic antibody (Ab2) to monoclonal antibodies BR55-2 (Ab1);

Group II, claims 20 22, drawn to a method of immunization which comprises administering a monoclonal antibody (Ab2);